Last reviewed · How we verify
Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin
This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria.
This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria. Used for Bacterial infections including respiratory tract infections, Urinary tract infections, Intra-abdominal infections.
At a glance
| Generic name | Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin |
|---|---|
| Also known as | Amoxicillin, Clavulanic acid |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Drug class | Beta-lactam antibiotics and aminoglycosides |
| Target | Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (30S subunit) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Augmentin (amoxicillin-clavulanate) inhibits bacterial cell wall synthesis via beta-lactamase inhibition. Ceftriaxone and cefotaxime are third-generation cephalosporins that also inhibit cell wall synthesis. Netilmicin and tobramycin are aminoglycosides that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. Together, these agents provide broad-spectrum coverage against gram-positive, gram-negative, and some anaerobic bacteria.
Approved indications
- Bacterial infections including respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Meningitis
- Sepsis
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reactions
- Nephrotoxicity (aminoglycosides)
- Ototoxicity (aminoglycosides)
- Pseudomembranous colitis
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: